Literature DB >> 8782343

MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice.

D A Higgins1, J R Carlson, G Van Nest.   

Abstract

The responses of young (8 week) and old (18 month) mice to influenza vaccine with and without the potent emulsion adjuvant MF59 were compared. In influenza naive mice, vaccine-specific antibody and T-cell proliferation were significantly lower in the old group compared to the young group. Post-immunization cytokine levels and antibody isotype profiles were different in the old compared to the young mice. The addition of the adjuvant MF59, a submicron oil-in-water emulsion composed of 5% v/v squalene, 0.5% v/v Tween 80 and 0.5% v/v Span 85, significantly increased the immune responses of both the young and old naive mice to the vaccine. The responses of the old mice given adjuvant increased to levels equivalent to those of young mice with vaccine alone. In mice previously infected with influenza virus, similarly depressed immune responses to vaccination were detected in the old mice. While the addition of MF59 to the vaccine had little effect on antibody titres of the previously infected young mice, the adjuvant significantly increased the antibody responses of the previously infected old mice. These results suggest that influenza vaccine combined with MF59 may significantly improve immune responses of elderly humans to influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782343     DOI: 10.1016/0264-410x(95)00240-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

2.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

3.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

4.  Profile of Rino Rappuoli.

Authors:  Bijal Trivedi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

5.  Invariant NKT cells sustain specific B cell responses and memory.

Authors:  Grazia Galli; Paola Pittoni; Elena Tonti; Carmine Malzone; Yasushi Uematsu; Marco Tortoli; Domenico Maione; Gianfranco Volpini; Oretta Finco; Sandra Nuti; Simona Tavarini; Paolo Dellabona; Rino Rappuoli; Giulia Casorati; Sergio Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

6.  Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza.

Authors:  Victor C Huber; Raelene M McKeon; Martha N Brackin; Laura A Miller; Rachael Keating; Scott A Brown; Natalia Makarova; Daniel R Perez; Gene H Macdonald; Jonathan A McCullers
Journal:  Clin Vaccine Immunol       Date:  2006-09

7.  A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV.

Authors:  Tiffany M Turner; Les P Jones; S Mark Tompkins; Ralph A Tripp
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

8.  Inflammatory responses to influenza vaccination at the extremes of age.

Authors:  Jacqueline U McDonald; Ziyun Zhong; Helen T Groves; John S Tregoning
Journal:  Immunology       Date:  2017-05-16       Impact factor: 7.397

9.  Towards identification of the mechanisms of action of parasite-derived peptide GK1 on the immunogenicity of an influenza vaccine.

Authors:  René Segura-Velázquez; Gladis Fragoso; Edda Sciutto; Adelaida Sarukhan
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

10.  A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.

Authors:  L Martínez-Gil; P H Goff; R Hai; A García-Sastre; M L Shaw; P Palese
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.